These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15470599)

  • 1. Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. PPAR and PTB1B modulators 26-27 July 2004, San Diego, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):836-8. PubMed ID: 15470599
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic Diseases Drug Discovery World Summit--SRI conference. 28-29 July 2003 San Diego, CA, USA.
    Knittel T
    IDrugs; 2003 Sep; 6(9):845-9. PubMed ID: 14565169
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):839-40. PubMed ID: 15470600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic Diseases World Summit 2005. Partnering and deal-making. 29 June-1 July 2005, San Francisco, CA, USA.
    Clark AG
    IDrugs; 2005 Sep; 8(9):708-9. PubMed ID: 16118687
    [No Abstract]   [Full Text] [Related]  

  • 6. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M; Gutman W; Derlacz RA
    Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein phosphorylation drug discovery summit--SRI conference. Targeting kinases and phosphatases for novel therapeutics. 3-5 March 2003, San Diego, CA, USA.
    Stokoe D
    IDrugs; 2003 May; 6(5):432-6. PubMed ID: 12841205
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicinal chemistry-XVIIIth International Symposium. Part II. 15-19 August 2004, Copenhagen, Denmark & Malmo, Sweden.
    Cheung CW
    IDrugs; 2004 Sep; 7(9):809-10. PubMed ID: 15470591
    [No Abstract]   [Full Text] [Related]  

  • 9. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Phosphorylation Drug Discovery Summit--SRI conference. Targeting kinases and phosphatases for novel therapeutics. 3-5 March 2003, San Diego, CA, USA.
    Hooft R
    IDrugs; 2003 Apr; 6(4):312-4. PubMed ID: 12839006
    [No Abstract]   [Full Text] [Related]  

  • 11. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy.
    Tobin JF; Freedman LP
    Trends Endocrinol Metab; 2006 Sep; 17(7):284-90. PubMed ID: 16870465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?
    Merk D; Schubert-Zsilavecz M
    Future Med Chem; 2012 Apr; 4(5):587-8. PubMed ID: 22458677
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic Diseases World Summit 2005. 29 June-1 July 2005, San Francisco, CA, USA.
    James S
    IDrugs; 2005 Sep; 8(9):704-7. PubMed ID: 16118686
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).
    Lamers C; Schubert-Zsilavecz M; Merk D
    Expert Opin Ther Pat; 2012 Jul; 22(7):803-41. PubMed ID: 22697317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
    Seneci P
    IDrugs; 2009 Jun; 12(6):358-62. PubMed ID: 19517315
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic Diseases Drug Discovery World Summit.
    Liu G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):577-82. PubMed ID: 14662006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARs: therapeutic targets for metabolic disease.
    Berger JP; Akiyama TE; Meinke PT
    Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
    Sarabu R
    Expert Opin Investig Drugs; 2003 Oct; 12(10):1721-6. PubMed ID: 14519091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.